Business
PRISM BioLab and Talus Bioscience Join Forces to Discover Novel Inhibitors of Transcription Factor and Protein-Protein Interaction Targets
PRISM BioLab, Co. Ltd. ("PRISM") and Talus Bioscience, Inc. ("Talus Bio") announced today that they entered into a collaboration to discover novel Inhibitors of transcription factor (TF) and protein-protein interaction (PPI) targets. By combining Talus Bio's assay technologies for screening for TF and PPI inhibitors in native cellular environment with PRISM's chemistry designed to target protein-protein interactions, companies are in a unique position to discover and develop drugs against these
About this update from Prism Biolab Co. Ltd
[{"type":"text","content":"TOKYO, Dec. 17, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM") and Talus Bioscience, Inc. ("Talus Bio") announced today that they entered into a collaboration to discover novel Inhibitors of transcription factor (TF) and protein-protein interaction (PPI) targets. By combining Talus Bio's assay technologies for screening for TF and PPI inhibitors in native cellular environment with PRISM's chemistry designed to target protein-protein interactions, companies are in a unique position to discover and develop drugs against these challenging targets.","length":585,"tagName":"p"},{"type":"image","alt":"PRISM BioLab logo (PRNewsfoto/PRISM BioLab Co., Ltd.)","displaySize":"","headline":null,"caption":"PRISM BioLab logo (PRNewsfoto/PRISM BioLab Co., Ltd.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":99,"url":"https://media.zenfs.com/en/prnewswire.com/d67e964c5280408946c03686dc3c0d59"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xRzCw3pY3D9VEjtsSb.3IA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE3NDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/d67e964c5280408946c03686dc3c0d59","width":400,"height":99}},"href":"https://mma.prnewswire.com/media/2693058/PRISM_BioLab_logo_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Under the agreement, the companies will deploy PRISM's proprietary small-molecule libraries in Talus Bio's AI-guided regulome profiling screens to identify and optimize novel compounds against high-value TF and PPI targets. The collaboration aims to generate first-in-class chemical matter with direct functional effects on TF and PPI activity in live human cells. Talus Bio and PRISM will share the costs of discovery research and development and any profits generated from out-licensing and commercialization of discovered drug products.","length":547,"tagName":"p"},{"type":"text","content":""We are delighted to partner with Talus Bio on this exciting project", commented Dai Takehara, PRISM's President and CEO. "We at PRISM have developed chemistries for PPI targets, but because of the complex nature of these targets, it is often challenging to properly model protein-protein interactions in a biochemical assay. Even when we are successful, we can interrogate only one target at a time, whereas Talus ...